The inspection was conducted from 17th March to 21st March, 2025. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
The company’s consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY).
The counter surged 13.62% to end at Rs 947.75 on the BSE on Friday.